Patent classifications
A61K31/375
MULTIPLE NUTRIENT LIPOSOMAL SUPPLEMENT AND METHODS OF MANUFACTURING THE SAME
Compositions and methods for increasing absorption of nutrients by a body. A composition includes a liposome comprising a lipid bilayer, wherein the liposome comprises an internal core. The composition includes a nutrient payload disposed within the liposome. The nutrient payload comprises a plurality of different supplement nutrients comprising one or more of a vitamin, mineral, extract, enzyme, or amino acid.
MULTIPLE NUTRIENT LIPOSOMAL SUPPLEMENT AND METHODS OF MANUFACTURING THE SAME
Compositions and methods for increasing absorption of nutrients by a body. A composition includes a liposome comprising a lipid bilayer, wherein the liposome comprises an internal core. The composition includes a nutrient payload disposed within the liposome. The nutrient payload comprises a plurality of different supplement nutrients comprising one or more of a vitamin, mineral, extract, enzyme, or amino acid.
A MULTICOMPONENT COMPOSITION COMPRISING A COLLAGEN, RESVERATROL AND ASTAXANTHIN AND THE USE THEREOF FOR THE TREATMENT OF TENDINOPATHIES
The present invention relates to compositions comprising collagen, resveratrol, astaxanthin, and vitamin C. Furthermore, the present invention relates to the use of said compositions for the treatment of tendinopathies and diseases affecting the joints or the musculoskeletal system.
A MULTICOMPONENT COMPOSITION COMPRISING A COLLAGEN, RESVERATROL AND ASTAXANTHIN AND THE USE THEREOF FOR THE TREATMENT OF TENDINOPATHIES
The present invention relates to compositions comprising collagen, resveratrol, astaxanthin, and vitamin C. Furthermore, the present invention relates to the use of said compositions for the treatment of tendinopathies and diseases affecting the joints or the musculoskeletal system.
A MULTICOMPONENT COMPOSITION COMPRISING A COLLAGEN, RESVERATROL AND ASTAXANTHIN AND THE USE THEREOF FOR THE TREATMENT OF TENDINOPATHIES
The present invention relates to compositions comprising collagen, resveratrol, astaxanthin, and vitamin C. Furthermore, the present invention relates to the use of said compositions for the treatment of tendinopathies and diseases affecting the joints or the musculoskeletal system.
Prenatal Dosage Forms, Methods of Administration and Kits Thereof
Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.
Prenatal Dosage Forms, Methods of Administration and Kits Thereof
Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.
Prenatal Dosage Forms, Methods of Administration and Kits Thereof
Disclosed herein are prenatal dosage forms formulated for different stages of the pregnancy cycle. Also disclosed are methods of administering prenatal dosage forms to a prenatal, pregnant or lactating woman. Further disclosed are kits including prenatal dosage forms.
TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT
A drug delivery system is provided for transdermally administering a psychedelic active agent to a subject to provide continuous microdose plasma levels of the active agent or a metabolite thereof during an extended drug delivery time period. The transdermal drug delivery system comprises a drug reservoir that houses a formulation containing the active agent, a combination of a solubilizer-type permeation enhancer and a plasticizer-type permeation enhancer, and a pH stabilizing agent. The pH stabilizing agent brings the pH of the formulation, at the system-skin interface, and/or within the skin as the active agent is transported across the skin from the skin surface to the bloodstream, to within 25% of the pKa of the active agent. Formulations and methods of use are also provided.
TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT
A drug delivery system is provided for transdermally administering a psychedelic active agent to a subject to provide continuous microdose plasma levels of the active agent or a metabolite thereof during an extended drug delivery time period. The transdermal drug delivery system comprises a drug reservoir that houses a formulation containing the active agent, a combination of a solubilizer-type permeation enhancer and a plasticizer-type permeation enhancer, and a pH stabilizing agent. The pH stabilizing agent brings the pH of the formulation, at the system-skin interface, and/or within the skin as the active agent is transported across the skin from the skin surface to the bloodstream, to within 25% of the pKa of the active agent. Formulations and methods of use are also provided.